CA2618380A1 - Feed additive and uses thereof - Google Patents
Feed additive and uses thereof Download PDFInfo
- Publication number
- CA2618380A1 CA2618380A1 CA002618380A CA2618380A CA2618380A1 CA 2618380 A1 CA2618380 A1 CA 2618380A1 CA 002618380 A CA002618380 A CA 002618380A CA 2618380 A CA2618380 A CA 2618380A CA 2618380 A1 CA2618380 A1 CA 2618380A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- animal
- food
- human
- anyone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003674 animal food additive Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 206010061218 Inflammation Diseases 0.000 claims abstract description 34
- 230000004054 inflammatory process Effects 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 32
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 24
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 24
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 229940088594 vitamin Drugs 0.000 claims abstract description 20
- 229930003231 vitamin Natural products 0.000 claims abstract description 20
- 239000011782 vitamin Substances 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 230000036760 body temperature Effects 0.000 claims abstract description 15
- -1 polyphenol compound Chemical class 0.000 claims abstract description 15
- 230000009885 systemic effect Effects 0.000 claims abstract description 15
- 239000000419 plant extract Substances 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims description 63
- 235000015872 dietary supplement Nutrition 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 23
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 10
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 6
- 239000006041 probiotic Substances 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 235000018291 probiotics Nutrition 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000001914 calming effect Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 230000035558 fertility Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229960001047 methyl salicylate Drugs 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 230000035882 stress Effects 0.000 abstract description 36
- 230000036542 oxidative stress Effects 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 239000006052 feed supplement Substances 0.000 abstract description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 19
- 229930003427 Vitamin E Natural products 0.000 description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 17
- 229940046009 vitamin E Drugs 0.000 description 17
- 235000019165 vitamin E Nutrition 0.000 description 17
- 239000011709 vitamin E Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 229960000984 tocofersolan Drugs 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- 235000004835 α-tocopherol Nutrition 0.000 description 11
- 239000002076 α-tocopherol Substances 0.000 description 11
- 229940087168 alpha tocopherol Drugs 0.000 description 10
- 150000002989 phenols Chemical class 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 241000207923 Lamiaceae Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 6
- 239000011648 beta-carotene Substances 0.000 description 6
- 235000013734 beta-carotene Nutrition 0.000 description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 6
- 229960002747 betacarotene Drugs 0.000 description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 6
- 229960001860 salicylate Drugs 0.000 description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 240000001238 Gaultheria procumbens Species 0.000 description 4
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 244000178231 Rosmarinus officinalis Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 235000001671 coumarin Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000011477 liquorice Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000021183 entrée Nutrition 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 3
- 208000031968 Cadaver Diseases 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000007673 Origanum vulgare Species 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 239000008047 antioxidant nutrient Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 229910000207 majorite Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DMBTYPPQYTYHFZ-UHFFFAOYSA-N 2-hydroxybenzoic acid methyl 2-hydroxybenzoate Chemical compound OC(=O)C1=CC=CC=C1O.COC(=O)C1=CC=CC=C1O DMBTYPPQYTYHFZ-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical class 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 125000001020 α-tocopherol group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a food or feed supplement composition. The composition comprised of a natural anti-inflammatory compound or plant extract, a anti-oxidant compound and a vitamin. The anti-inflammatory compound is preferably a polyphenol compound.
The composition helps to reduce the body oxidative stress, the systemic or localised inflammation, or the body temperature due to stress.
The composition helps to reduce the body oxidative stress, the systemic or localised inflammation, or the body temperature due to stress.
Description
FEED ADDITIVE AND USES THEREOF
Field of the invention This invention is in the area of animal feed additives.
Background of the invention Disease or undesirable condition may occur in a human and an animal subject from any one or more of a long list of causes, including microbial infection, exposure to toxins, prolonged exposure to stress, and a diet that is either deficient in one or more essential substances, contains an excess of harmful substances, such as salt, fats, cholesterol, etc., or is otherwise unbalanced.
Alternatively, or in addition, the onset and development of disease or undesirable condition may have a genetic component.
Oxidative damage is caused by the action of highly reactive species (such as free radicals or peroxides) on the cells and tissues of the body. A free radical is any atom or group of atoms, which has one or more uripaired electrons. Free radicals are uncharged high-energy species that are highly reactive. Peroxides are compounds containing linked pairs of oxygen atoms.
Organic peroxides can act as sources of free radicals.
One major source of such reactive species is molecular oxygen, which is converted into a "reactive oxygen species". The loss of an electron from molecular oxygen will produce a free radical species, which reacts with cells or tissue in the body causing damage including lipid peroxidation, which leads to cell death. Reactive oxygen species can be produced in the body of an aerobic organism during metabolism, for example by the respiratory burst of phagocytes, mitochondrial oxidative phosphorylation and the xanthine oxidase system. In addition, reactive oxygen species are produced in the environment, for example by UV light, pollutants or ionising radiation.
Exposure of the body to agents causing oxidative damage results in inflammation, auto immune diseases, cancers, muscle disorders, lung inflammation and general ageing. Oxidative damage to different parts of the body is responsible for causing or exacerbating a number of disorders. Oxidative stress occurs when the production of reactive oxygen species exceeds the removal of the reactive oxygen species. Systemic and localised inflammation most of the time involve reaction of oxidative stresses and production of inflammatory markers, such as protein kinase C, lactic acid, haptogrobin, and cortisol. Another consequence of oxidative stress, body temperature increases and/or systemic inflammation is the reduction of oxygenation of cells, particularly smooth and red muscle cells, as well as the equilibrium of the immune and hormonal systems.
Agents causing oxidative damage can be inactivated by antioxidant molecules or compounds. Antioxidants are typically highly substituted phenols, aromatic amines or sulphur containing molecules, which can occur naturally or can be produced synthetically. In addition, metal-sequestering agents can act as antioxidants by inactivating metals. The body has its own anti-oxidant defences including glutathione, vitamin C, vitamin E, catalase, copper-zinc-superoxide dismutase and uric acid.
In moderate or severe cases of body temperature decrease, systemic and localised inflammation, and oxidative -stress, it is necessary to treat with prescription medication.
Corticosteroids are most of the time used to reduce the inflammation thereby resolving the clinical signs of the disease. However, the inflammation will return following cessation of the therapy if the individual is exposed to offending products or conditions, including environmental sources of stress. The use of corticosteroids is accompanied by a number of undesirable side effects. High concentrations of the corticosteroids result in the suppression of the immune system. The long-term use of corticosteroids can lead to depression, muscle wasting, long dry hair coat, hyperglycemia, increased risk of' laminitis, polydipsia and polyuria.
Phosphodiesterase inhibitors inhibit the breakdown of intracellular cAMP in smooth muscle. The most commonly used phosphodiesterase inhibitor in mammals is theophylline.
In addition, stress causing body temperature disturbance and systemic inflammation leads to lost of performance in animal production systems and farms. Appetite reduction, weight loss, decrease survival rate at birth, reduction of delivery, reduction of lactation, and several other problems can be associated to stress effects to the body.
Field of the invention This invention is in the area of animal feed additives.
Background of the invention Disease or undesirable condition may occur in a human and an animal subject from any one or more of a long list of causes, including microbial infection, exposure to toxins, prolonged exposure to stress, and a diet that is either deficient in one or more essential substances, contains an excess of harmful substances, such as salt, fats, cholesterol, etc., or is otherwise unbalanced.
Alternatively, or in addition, the onset and development of disease or undesirable condition may have a genetic component.
Oxidative damage is caused by the action of highly reactive species (such as free radicals or peroxides) on the cells and tissues of the body. A free radical is any atom or group of atoms, which has one or more uripaired electrons. Free radicals are uncharged high-energy species that are highly reactive. Peroxides are compounds containing linked pairs of oxygen atoms.
Organic peroxides can act as sources of free radicals.
One major source of such reactive species is molecular oxygen, which is converted into a "reactive oxygen species". The loss of an electron from molecular oxygen will produce a free radical species, which reacts with cells or tissue in the body causing damage including lipid peroxidation, which leads to cell death. Reactive oxygen species can be produced in the body of an aerobic organism during metabolism, for example by the respiratory burst of phagocytes, mitochondrial oxidative phosphorylation and the xanthine oxidase system. In addition, reactive oxygen species are produced in the environment, for example by UV light, pollutants or ionising radiation.
Exposure of the body to agents causing oxidative damage results in inflammation, auto immune diseases, cancers, muscle disorders, lung inflammation and general ageing. Oxidative damage to different parts of the body is responsible for causing or exacerbating a number of disorders. Oxidative stress occurs when the production of reactive oxygen species exceeds the removal of the reactive oxygen species. Systemic and localised inflammation most of the time involve reaction of oxidative stresses and production of inflammatory markers, such as protein kinase C, lactic acid, haptogrobin, and cortisol. Another consequence of oxidative stress, body temperature increases and/or systemic inflammation is the reduction of oxygenation of cells, particularly smooth and red muscle cells, as well as the equilibrium of the immune and hormonal systems.
Agents causing oxidative damage can be inactivated by antioxidant molecules or compounds. Antioxidants are typically highly substituted phenols, aromatic amines or sulphur containing molecules, which can occur naturally or can be produced synthetically. In addition, metal-sequestering agents can act as antioxidants by inactivating metals. The body has its own anti-oxidant defences including glutathione, vitamin C, vitamin E, catalase, copper-zinc-superoxide dismutase and uric acid.
In moderate or severe cases of body temperature decrease, systemic and localised inflammation, and oxidative -stress, it is necessary to treat with prescription medication.
Corticosteroids are most of the time used to reduce the inflammation thereby resolving the clinical signs of the disease. However, the inflammation will return following cessation of the therapy if the individual is exposed to offending products or conditions, including environmental sources of stress. The use of corticosteroids is accompanied by a number of undesirable side effects. High concentrations of the corticosteroids result in the suppression of the immune system. The long-term use of corticosteroids can lead to depression, muscle wasting, long dry hair coat, hyperglycemia, increased risk of' laminitis, polydipsia and polyuria.
Phosphodiesterase inhibitors inhibit the breakdown of intracellular cAMP in smooth muscle. The most commonly used phosphodiesterase inhibitor in mammals is theophylline.
In addition, stress causing body temperature disturbance and systemic inflammation leads to lost of performance in animal production systems and farms. Appetite reduction, weight loss, decrease survival rate at birth, reduction of delivery, reduction of lactation, and several other problems can be associated to stress effects to the body.
-2-Therefore any new treatment or therapy which allows decreasing the concentration of conventional pharmaceuticals necessary to treat stress, inflammation and body temperature will be beneficial, in addition of improving the human and animal welfare and performance.
SUMMARY OF THE INVENTION
One aim of the present invention is to provide a food supplement composition comprising at least one polyphenol compound, at least one antioxidant compound, and at least one vitamin.
The polyphenol compound can be obtained from a plant extract, and for example, but without limiting the scope of the present invention, can be a polyphenolic acid. The vitamin can be an antioxidant vitamin, or another vitamin, such as for example, vitamin D, or a vitamin B, or a vitamin f, or a combination thereof.
For example, the polyphenol can be in proportion of 0.1% (w/v or w/w) to 25%
(w/v or w/w), the anti-oxidant compound in proportion of 0.1% (w/v or w/w) to 20% (w/v or w/w), and the vitamin in proportion of 0.11ro (w/v or w/w) to 30% (w/v or w/w).
In accordance with the present invention there is provided a food composition in which can be a concentration of methyl salicylate or an analog thereof at a level from 0.01 mg to 100 mg per kilogram body weight per day or above.
The food supplemenit composition of the present invention may comprosed of a probiotic microorganism. The probiotic microorganism can be a yeast, a bacteria, or a combination thereof, which can be alternatibly a living or dead probiotic microorganism.
Another aim of the present invention is to provide a food supplement for reducing systemic inflammation, localised inflammation, body temperature, or cellular oxidation, comprising a food supplement composition as described herein.
Another aim of the present invention is to provide a method for reducing body temperature, systemic inflammation, localised inflammation, or cellular oxidation, the method
SUMMARY OF THE INVENTION
One aim of the present invention is to provide a food supplement composition comprising at least one polyphenol compound, at least one antioxidant compound, and at least one vitamin.
The polyphenol compound can be obtained from a plant extract, and for example, but without limiting the scope of the present invention, can be a polyphenolic acid. The vitamin can be an antioxidant vitamin, or another vitamin, such as for example, vitamin D, or a vitamin B, or a vitamin f, or a combination thereof.
For example, the polyphenol can be in proportion of 0.1% (w/v or w/w) to 25%
(w/v or w/w), the anti-oxidant compound in proportion of 0.1% (w/v or w/w) to 20% (w/v or w/w), and the vitamin in proportion of 0.11ro (w/v or w/w) to 30% (w/v or w/w).
In accordance with the present invention there is provided a food composition in which can be a concentration of methyl salicylate or an analog thereof at a level from 0.01 mg to 100 mg per kilogram body weight per day or above.
The food supplemenit composition of the present invention may comprosed of a probiotic microorganism. The probiotic microorganism can be a yeast, a bacteria, or a combination thereof, which can be alternatibly a living or dead probiotic microorganism.
Another aim of the present invention is to provide a food supplement for reducing systemic inflammation, localised inflammation, body temperature, or cellular oxidation, comprising a food supplement composition as described herein.
Another aim of the present invention is to provide a method for reducing body temperature, systemic inflammation, localised inflammation, or cellular oxidation, the method
-3-comprising the step of administering orally to an animal or a human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for improving fertility of an animal or a human compris'ing giving orally to the animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for increasing the growth rate of an animal or a human comprising giving orally to an animal or a human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for calming an animal or a human comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for reducing body shrink of an animal or a human during a stress period comprising giving orally to an animal or human the food supplement composition according to the present invention at least before, during, or after the stress period.
Another aim of the present invention is to provide a method for increasing the number of eggs per bird comprising giving orally to a bird the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for reducing diarrhea of an animal or a human comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for increasing wounding comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for improving fertility of an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for improving fertility of an animal or a human compris'ing giving orally to the animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for increasing the growth rate of an animal or a human comprising giving orally to an animal or a human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for calming an animal or a human comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for reducing body shrink of an animal or a human during a stress period comprising giving orally to an animal or human the food supplement composition according to the present invention at least before, during, or after the stress period.
Another aim of the present invention is to provide a method for increasing the number of eggs per bird comprising giving orally to a bird the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for reducing diarrhea of an animal or a human comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a method for increasing wounding comprising giving orally to an animal or human the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for improving fertility of an animal or a human comprising the food supplement composition according to the present invention.
-4-Another aim of the present invention is to provide a food composition for increasing the growth rate of an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for calming an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for reducing body shrink of an animal or a human during a stress period comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for increasing the number of eggs per bird compr:ising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for reducing diarrhea of an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for increasing wounding comprising the food supplement composition according to the present invention.
For the purpose of the present invention the following terms are defined below.
For the purposes of this invention, the terms "aid" and "aiding" mean to decrease or alleviate the symptoms suffered by a human or an animal individual especially the symptoms of systemic inflammation, body temperature increase, and stress effects. This aid may allow the reliance on a drug therapy to be reduced. Alternatively the individual may exhibit less symptoms or the severity of the symptoms may be reduced. The individual may exhibit an improved level of fitness or an improved level of well being.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This
Another aim of the present invention is to provide a food composition for calming an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for reducing body shrink of an animal or a human during a stress period comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for increasing the number of eggs per bird compr:ising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for reducing diarrhea of an animal or a human comprising the food supplement composition according to the present invention.
Another aim of the present invention is to provide a food composition for increasing wounding comprising the food supplement composition according to the present invention.
For the purpose of the present invention the following terms are defined below.
For the purposes of this invention, the terms "aid" and "aiding" mean to decrease or alleviate the symptoms suffered by a human or an animal individual especially the symptoms of systemic inflammation, body temperature increase, and stress effects. This aid may allow the reliance on a drug therapy to be reduced. Alternatively the individual may exhibit less symptoms or the severity of the symptoms may be reduced. The individual may exhibit an improved level of fitness or an improved level of well being.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This
-5-invention, may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein, rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
In accordance with the present invention, there is provided a food supplement comprising at least one polyphenol compound, at least one antioxidant compound, and at least one vitamin.
The polyphenol compound can be a polyphenolic adic, which is generally obtained from natural sources and plants, under form, for example but not limited to, plant extracts. Again for example, polyphenol can be obtained from liquorice, wintergreen, betula, taxus, larix, rosemary, grape seeds, or combination thereof.
According to another embodiment of the present invention there is provided a food or feed supplement providing a synergistic effect of the combination of anti-inflammatory products, preferably natural, and alimentary anti-oxidant products, with vitamins.
Also, the present invention may also contain one or more flavenoids from natural and synthetic sources. The source of the flavenoid is not limiting. More preferably, the natural source of flavenoids is one or more of' wintergreen, rosemary and liquorice. The plants contain tannic acid, resin and a volatile oil, which contains Borneol, bornyl acetate and other esters and a camphor derivative. Oil of rosemary is used as a tonic, astringent, diaphoretic and stimulant.
Dried plant extract containing polyphenol or flavanoids is provided at levels of from 0.1 mg to 10 grams per kilogram body weight per day, preferably at levels of 10 mg to l gram per kilogram bodyweight per day, and above or an equivalent amount of a semi-dried or fully hydrated form of plant extract.
Among others, liquorice has been shown to contain active saponins including glycyrrhizin. These compounds have been reported to have liver-protective effects through their anti-free radical properties. Glycyrrhizin is converted into its aglycone by intestinal flora.
Flavonoid aglycones are very bio-available.
In accordance with the present invention, there is provided a food supplement comprising at least one polyphenol compound, at least one antioxidant compound, and at least one vitamin.
The polyphenol compound can be a polyphenolic adic, which is generally obtained from natural sources and plants, under form, for example but not limited to, plant extracts. Again for example, polyphenol can be obtained from liquorice, wintergreen, betula, taxus, larix, rosemary, grape seeds, or combination thereof.
According to another embodiment of the present invention there is provided a food or feed supplement providing a synergistic effect of the combination of anti-inflammatory products, preferably natural, and alimentary anti-oxidant products, with vitamins.
Also, the present invention may also contain one or more flavenoids from natural and synthetic sources. The source of the flavenoid is not limiting. More preferably, the natural source of flavenoids is one or more of' wintergreen, rosemary and liquorice. The plants contain tannic acid, resin and a volatile oil, which contains Borneol, bornyl acetate and other esters and a camphor derivative. Oil of rosemary is used as a tonic, astringent, diaphoretic and stimulant.
Dried plant extract containing polyphenol or flavanoids is provided at levels of from 0.1 mg to 10 grams per kilogram body weight per day, preferably at levels of 10 mg to l gram per kilogram bodyweight per day, and above or an equivalent amount of a semi-dried or fully hydrated form of plant extract.
Among others, liquorice has been shown to contain active saponins including glycyrrhizin. These compounds have been reported to have liver-protective effects through their anti-free radical properties. Glycyrrhizin is converted into its aglycone by intestinal flora.
Flavonoid aglycones are very bio-available.
-6-For the purposes of this invention the plant extract may be dried or partially dried, in the fornl of a powder, in oil, liquid (either as a solution or as an oil), crushed, an extract, fresh or semi-solid. Preferred forms of clried plant extract include those containing between 0 and 40%
w/w water or between 0 and 10% or between 0 and 5%. Dried liquorice is preferably provided at a level of 2 mg to 500 mg per kilogram bodyweight per day more preferably 1 mg per kilogram bodyweight per day or above.
The first aspect of the invention relates to a food supplement which may contain herbal phenolic compounds. The source of the herbal phenolic compounds is not limiting and can include natural and synthetic sources. The herbal phenolic compounds can be provided by a natural source such as a plant, more preferably an herb plant. The phenolic compounds can be provided by one herb or by a mixture of herbs, for example, one or more of wintergreen, rosemary, nutmeg, oregano, basil and coriander. For the purposes of this invention, any part of the herb plant can be used (for exarnple, leaf, stem, bark, bulb, root, fruit, flower or seed). The herb material can be dried, semi-dried, fresh, crushed, in oil, in solution as a powder, liquid (as a solution or as an oil) or semi-soli:d.
Alternatively, the herbal phenolic compound is provided as an extract from a plant.
The phenolic compound can be extracted and partially or fully purified from the herb.
Preferably the phenolic compounds are obtained from wintergreen.
Several phenolic cornpounds extracted from plant extracts as disclosed above (and related family members such as oregano) have exhibited antioxidant effects.
Phenolics from plant extracts include, but are not limited to, carnosol, rosemanol, carnosic acid and rosemaridiphenol.
These phenolic compounds may act as antioxidants, inhibit carcinogenesis or act as anti-inflammatory agents.
Plant extracts according to the the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
Another aspect of die invention may optionally comprise proanthrocyanidins.
The proanthrocyanidins of the preser-t invention can be provided by natural or synthetic sources. The
w/w water or between 0 and 10% or between 0 and 5%. Dried liquorice is preferably provided at a level of 2 mg to 500 mg per kilogram bodyweight per day more preferably 1 mg per kilogram bodyweight per day or above.
The first aspect of the invention relates to a food supplement which may contain herbal phenolic compounds. The source of the herbal phenolic compounds is not limiting and can include natural and synthetic sources. The herbal phenolic compounds can be provided by a natural source such as a plant, more preferably an herb plant. The phenolic compounds can be provided by one herb or by a mixture of herbs, for example, one or more of wintergreen, rosemary, nutmeg, oregano, basil and coriander. For the purposes of this invention, any part of the herb plant can be used (for exarnple, leaf, stem, bark, bulb, root, fruit, flower or seed). The herb material can be dried, semi-dried, fresh, crushed, in oil, in solution as a powder, liquid (as a solution or as an oil) or semi-soli:d.
Alternatively, the herbal phenolic compound is provided as an extract from a plant.
The phenolic compound can be extracted and partially or fully purified from the herb.
Preferably the phenolic compounds are obtained from wintergreen.
Several phenolic cornpounds extracted from plant extracts as disclosed above (and related family members such as oregano) have exhibited antioxidant effects.
Phenolics from plant extracts include, but are not limited to, carnosol, rosemanol, carnosic acid and rosemaridiphenol.
These phenolic compounds may act as antioxidants, inhibit carcinogenesis or act as anti-inflammatory agents.
Plant extracts according to the the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
Another aspect of die invention may optionally comprise proanthrocyanidins.
The proanthrocyanidins of the preser-t invention can be provided by natural or synthetic sources. The
-7-source of the proanthrocyanidins is not limiting. The proanthrocyanidins can also be provided by grape seed oil for example, without limiting the invention to this source.
The food supplement of the invention optionally contains B-vitamins including folate.
The B-vitamins can be provided by natural or synthetic sources. Definitions of natural and synthetic sources discussed in relation to the antioxidant vitamins also apply to this aspect of the invention. Natural sources of the B vitamins include brewers yeast.
Brewers yeast is provided in the food supplement in this aspect of the invention at a level from lmg to 25 grams per kilogram body weight per day.
The food supplement of the invention may be used in aiding the treatment of an animal suffering from high body temperature, systemic inflammation, localized inflammation, oxidative stress, or environmental stress effects. In particular the food supplement is used where the animal may be mammals or birds. Manimals for the purposes of this invention include bovine, porcine, ovine, caprine, feline, canine, and primate, including human being. Birds may include for example chicken, turkey or ducks.
The antioxidant vitamins of the invention are compounds which can inactivate free radical species or the sources of free radicals including reactive oxygen species and hydrogen peroxide. Examples of such antioxidant vitamins include vitamin C, vitamin E
and beta-carotene.
Vitamin C is a water-soluble substance. Vitamin C has a number of important roles in the body. It has an essential role in the maintenance of healthy teeth, gums and bones. It aids the healing of wounds, scar tissue and fractures and strengthens blood vessels.
Vitamin C also builds resistance to infection and aids in the prevention and treatment of the common cold. Vitamin C is also one of the major antioxidant nutrients.
The food supplement of the invention will optionally contain vitamin C at a level from 10 mg to 1 gram per kilogram body weight per day. The vitamin C may be in any form. It may be liquid, semi-solid or solid.
Vitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity. The selenium-containing enzyme glutathione peroxidase together with vitamin E helps to protect cells against
The food supplement of the invention optionally contains B-vitamins including folate.
The B-vitamins can be provided by natural or synthetic sources. Definitions of natural and synthetic sources discussed in relation to the antioxidant vitamins also apply to this aspect of the invention. Natural sources of the B vitamins include brewers yeast.
Brewers yeast is provided in the food supplement in this aspect of the invention at a level from lmg to 25 grams per kilogram body weight per day.
The food supplement of the invention may be used in aiding the treatment of an animal suffering from high body temperature, systemic inflammation, localized inflammation, oxidative stress, or environmental stress effects. In particular the food supplement is used where the animal may be mammals or birds. Manimals for the purposes of this invention include bovine, porcine, ovine, caprine, feline, canine, and primate, including human being. Birds may include for example chicken, turkey or ducks.
The antioxidant vitamins of the invention are compounds which can inactivate free radical species or the sources of free radicals including reactive oxygen species and hydrogen peroxide. Examples of such antioxidant vitamins include vitamin C, vitamin E
and beta-carotene.
Vitamin C is a water-soluble substance. Vitamin C has a number of important roles in the body. It has an essential role in the maintenance of healthy teeth, gums and bones. It aids the healing of wounds, scar tissue and fractures and strengthens blood vessels.
Vitamin C also builds resistance to infection and aids in the prevention and treatment of the common cold. Vitamin C is also one of the major antioxidant nutrients.
The food supplement of the invention will optionally contain vitamin C at a level from 10 mg to 1 gram per kilogram body weight per day. The vitamin C may be in any form. It may be liquid, semi-solid or solid.
Vitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity. The selenium-containing enzyme glutathione peroxidase together with vitamin E helps to protect cells against
-8-free radical induced damage. Vitamin E acts as a scavenger of free radicals.
Vitamin C may assist by reducing the tocopheroxyl radicals formed by the scavenging. In addition, vitamin E helps to block lipid peroxidation and may also form an important part of the membrane structure due to its interaction with membrane phospholipids. It has also been suggested that Vitamin E plays an important role in the functioning of the immune system. The most biologically active biological form of vitamin E in animal tissue is alpha-tocopherol. Vitamin E cannot be synthesised in vivo.
Forms of vitamin E for the present invention include D-alpha-tocopherol, D-alpha-tocopherol acetate, DL-alpha-tocopherol and DL-alpha-tocopherol acetate.
Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha-tocopherol approximates to 1 mg of alpha-tocopherol. Other vitamin E compounds have their IU
determined by their biopotency :in comparison to alpha-tocopherol as described in McDowell, L.
R (1989) Vitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.
Vitamin E is a major anti-oxidant nutrient and acts in the body as a free radical scavenger. Alpha-tocopherol is the most active anti-oxidant biological form of vitamin E.
The food supplement of the first aspect of the invention may contain vitamin E
at a level from 1 IU to 100 IU per kilogram body weight per day.
A further useful point: in relation to the use of vitamin E in combination with vitamin C
is their potential to act synergistically, and more again when in combination with anti-inflammatory plant extract, such as these containing polyphenolic acids. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol.
Beta-carotene has strong antioxidant properties and has been shown to be beneficial against selected cancers, cardiovascular diseases, cataracts and age related macular degeneration.
Beta-carotene is particularly effective at scavenging peroxyl radicals and is a very potent singlet oxygen quencher at low oxygen tensions. Supplementation of the diet with beta-carotene has been reported to reduce lipid peroxidation.
Vitamin C may assist by reducing the tocopheroxyl radicals formed by the scavenging. In addition, vitamin E helps to block lipid peroxidation and may also form an important part of the membrane structure due to its interaction with membrane phospholipids. It has also been suggested that Vitamin E plays an important role in the functioning of the immune system. The most biologically active biological form of vitamin E in animal tissue is alpha-tocopherol. Vitamin E cannot be synthesised in vivo.
Forms of vitamin E for the present invention include D-alpha-tocopherol, D-alpha-tocopherol acetate, DL-alpha-tocopherol and DL-alpha-tocopherol acetate.
Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha-tocopherol approximates to 1 mg of alpha-tocopherol. Other vitamin E compounds have their IU
determined by their biopotency :in comparison to alpha-tocopherol as described in McDowell, L.
R (1989) Vitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.
Vitamin E is a major anti-oxidant nutrient and acts in the body as a free radical scavenger. Alpha-tocopherol is the most active anti-oxidant biological form of vitamin E.
The food supplement of the first aspect of the invention may contain vitamin E
at a level from 1 IU to 100 IU per kilogram body weight per day.
A further useful point: in relation to the use of vitamin E in combination with vitamin C
is their potential to act synergistically, and more again when in combination with anti-inflammatory plant extract, such as these containing polyphenolic acids. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol.
Beta-carotene has strong antioxidant properties and has been shown to be beneficial against selected cancers, cardiovascular diseases, cataracts and age related macular degeneration.
Beta-carotene is particularly effective at scavenging peroxyl radicals and is a very potent singlet oxygen quencher at low oxygen tensions. Supplementation of the diet with beta-carotene has been reported to reduce lipid peroxidation.
-9-The food supplement of the invention may contain beta-carotene as a level of from 1 mg to 50 mg per kilogram body weight per day.
The antioxidant vitamins (including sources of such vitamins, such as beta-carotene) of the invention are provided in combination with one or more compounds, which exhibit antioxidant or anti-inflammatory properties. These compounds include polyphenol, polyphenolic acid, eugenol, selenium, carotenoids, flavenoids, phyto-oestrogens, proanthrocyanidins, herbal phenolic compounds or ubiquinone.
Without limiting the present invention, there is some evidence that reactive oxygen species may have a role in high body temperature, stress related and inflammatory diseases. Work has indicated that mammals and birds suffering from recurrent airway obstruction demonstrate oxidative stress. The food supplement of the invention has provided a cocktail of antioxidant compounds derived from natural sources which decreases the level of inflammation in mammals and birds suffering from high body temperature, systemic and localized inflammations, and related conditions.
Administration of the food supplement of the invention to an animal will provide an increased level of compounds with antioxidant activity thus reducing oxidative stress to the body.
This will be particularly beneficial where an animal has been or will be or is subjected to an increase growth, or where an animal is exposed to free radicals due to environment. The food supplement may help in maintaining the healthy respiratory system of an animal by supporting or improving the natural defenses of the body.
Controlling the systemic or localized inflammation, or body temperature increase in farm animals by giving the animals a composition according to the present invenitori involves preventing further attacks by erivironmental management or the use of prescription medication which can be costly and involves the risk of unwanted side effects.
Administration of the food supplement of the invention cani reduce the need for prescription medication thereby decreasing the risk of side effects to that medication.
A second aspect of the invention provides a food supplement, which provides an effective prophylaxis or adjunct treatment for inflammation, stresses, stress effects or body
The antioxidant vitamins (including sources of such vitamins, such as beta-carotene) of the invention are provided in combination with one or more compounds, which exhibit antioxidant or anti-inflammatory properties. These compounds include polyphenol, polyphenolic acid, eugenol, selenium, carotenoids, flavenoids, phyto-oestrogens, proanthrocyanidins, herbal phenolic compounds or ubiquinone.
Without limiting the present invention, there is some evidence that reactive oxygen species may have a role in high body temperature, stress related and inflammatory diseases. Work has indicated that mammals and birds suffering from recurrent airway obstruction demonstrate oxidative stress. The food supplement of the invention has provided a cocktail of antioxidant compounds derived from natural sources which decreases the level of inflammation in mammals and birds suffering from high body temperature, systemic and localized inflammations, and related conditions.
Administration of the food supplement of the invention to an animal will provide an increased level of compounds with antioxidant activity thus reducing oxidative stress to the body.
This will be particularly beneficial where an animal has been or will be or is subjected to an increase growth, or where an animal is exposed to free radicals due to environment. The food supplement may help in maintaining the healthy respiratory system of an animal by supporting or improving the natural defenses of the body.
Controlling the systemic or localized inflammation, or body temperature increase in farm animals by giving the animals a composition according to the present invenitori involves preventing further attacks by erivironmental management or the use of prescription medication which can be costly and involves the risk of unwanted side effects.
Administration of the food supplement of the invention cani reduce the need for prescription medication thereby decreasing the risk of side effects to that medication.
A second aspect of the invention provides a food supplement, which provides an effective prophylaxis or adjunct treatment for inflammation, stresses, stress effects or body
-10-temperature increase. The food supplement may be manufactured from natural sources and provides a more natural treatment for this condition.
A further aspect of the invention provides a food supplement, which provides a contribution to the effective prophylaxis or treatment of systemic inflammation, body increase temperature, and stress effects. Administration of the food supplement of the invention to an individual suffering from these diseases will decrease, thus decreasing the severity of the symptoms.
According to anothei- embodiment of the current invention, it involves a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from damages dues to oxidative stress, body temperature increase, systemic or localized inflammation. The invention also relates to a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering froni an environmental stress effect. In particular this relates to a method of treatment where the stress effect involves an inflammation of the body. It is clear that the method may have more general effects throughout the body. In each case, the method comprises administering to the animal a food supplement of of the invention.
The animal is preferably in need of the prophylaxis or treatment.
The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
A further aspect of the invention provides a food supplement, which provides a contribution to the effective prophylaxis or treatment of systemic inflammation, body increase temperature, and stress effects. Administration of the food supplement of the invention to an individual suffering from these diseases will decrease, thus decreasing the severity of the symptoms.
According to anothei- embodiment of the current invention, it involves a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from damages dues to oxidative stress, body temperature increase, systemic or localized inflammation. The invention also relates to a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering froni an environmental stress effect. In particular this relates to a method of treatment where the stress effect involves an inflammation of the body. It is clear that the method may have more general effects throughout the body. In each case, the method comprises administering to the animal a food supplement of of the invention.
The animal is preferably in need of the prophylaxis or treatment.
The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
-11-EXEMPLE I
EFFET DES POLYPHENOLS ISSU DES HUILES DE THE DES BOIS, MENTHE
POIVRE ET DE CANNELLE COMME ADDITIF DE CONTROLE DES STRESS
D'ELEVAGE PORCIN
Abstract : Le stress est un probleme de production extremement grave. Le stress semble le principal element responsable de la majorite des pertes de production. Le stress est une reaction naturelle de l'organisme. Le stress est un mecanisme inflammatoire qui inhibe la production toutes les autres fonctions du corps pour permettre dans un premier temps de produire du sucre et ainsi etre en mesure de repondre aux attaques externes. (The mechanisms of body function 1984). Les quatre dernieres annees ont favorise des nouvelles approches de production animale et I'ajout de nouvelles alternatives qui permettent de reduire les problemes du stress. (Bristol University UK, animal welfare guide 2005). L'alimentation est aussi un moyen de reduire les stress ou du moins a aide de les controler.
L'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser un meilleur equilibre metabolique. L'objectif de cet ouvrage etait de demontrer si il est possible par I'alimentation d'augmenter la tolerance ou resistance aux differents stress d'elevage chez le porc.
Tableau 1 Matieres actives Nom de Ia plante Forme Origine Matiere active globale Matiere active physiqu desirer pour Ia e formulation INGREDIENTS AUX PROPRIETES ANTI-INFLAMMATOIRES
Reglisse de chine Poudre Asie isoflavones, liquiritine, isoliquirie et Ortho acethyle salicylate formoneitine, ortho acetyle salicylate de (Glucosides sodium phenoliques) Huile de the des bois Huile Europe et Methyle salicylate Methyl salicylate Asie (Glucosides phenoliques) Menthe poivree Poudre Europe et Menthol, acides phenoliques Acide phenolique Asie Vitamine E Poudre Asie Alpha tocopherol Vitamine E
INGREDIENTS AUX PROPRIETES regularisation du sucre sanguin Tripicolinate de Poudre USA Chrome Chrome chrome INGREDIENTS SIALAGOGUE ET BACTERIOSTATIQUES
Huile de cannelle Huile Amerique Aldehyde cinnamique, eugenol, tanins, Aldehyde cinnamique, du sud, coumarines coumarines Europe et Asie
EFFET DES POLYPHENOLS ISSU DES HUILES DE THE DES BOIS, MENTHE
POIVRE ET DE CANNELLE COMME ADDITIF DE CONTROLE DES STRESS
D'ELEVAGE PORCIN
Abstract : Le stress est un probleme de production extremement grave. Le stress semble le principal element responsable de la majorite des pertes de production. Le stress est une reaction naturelle de l'organisme. Le stress est un mecanisme inflammatoire qui inhibe la production toutes les autres fonctions du corps pour permettre dans un premier temps de produire du sucre et ainsi etre en mesure de repondre aux attaques externes. (The mechanisms of body function 1984). Les quatre dernieres annees ont favorise des nouvelles approches de production animale et I'ajout de nouvelles alternatives qui permettent de reduire les problemes du stress. (Bristol University UK, animal welfare guide 2005). L'alimentation est aussi un moyen de reduire les stress ou du moins a aide de les controler.
L'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser un meilleur equilibre metabolique. L'objectif de cet ouvrage etait de demontrer si il est possible par I'alimentation d'augmenter la tolerance ou resistance aux differents stress d'elevage chez le porc.
Tableau 1 Matieres actives Nom de Ia plante Forme Origine Matiere active globale Matiere active physiqu desirer pour Ia e formulation INGREDIENTS AUX PROPRIETES ANTI-INFLAMMATOIRES
Reglisse de chine Poudre Asie isoflavones, liquiritine, isoliquirie et Ortho acethyle salicylate formoneitine, ortho acetyle salicylate de (Glucosides sodium phenoliques) Huile de the des bois Huile Europe et Methyle salicylate Methyl salicylate Asie (Glucosides phenoliques) Menthe poivree Poudre Europe et Menthol, acides phenoliques Acide phenolique Asie Vitamine E Poudre Asie Alpha tocopherol Vitamine E
INGREDIENTS AUX PROPRIETES regularisation du sucre sanguin Tripicolinate de Poudre USA Chrome Chrome chrome INGREDIENTS SIALAGOGUE ET BACTERIOSTATIQUES
Huile de cannelle Huile Amerique Aldehyde cinnamique, eugenol, tanins, Aldehyde cinnamique, du sud, coumarines coumarines Europe et Asie
-12-Tableau 2 Formulation en pourcentage d'ingredients utilises.
Ingredients Formule avant Formule A: Groupe A Formule Placebo substitution % % %
Composantes Methyle salicylate de I'huile de 0,0% 4,0% AUCUN
phytoactives the O-salicylate de la reglisse 12,5% 4,5%
Acide phenolique 0,5% 2,5%
Aldehyde cinnamique 0,5% 1,0%
Coumarines 0,25% 1,0%
Tanin 0,25% 1,0%
Composantes Vitamine E 64 K U.I. ou en premix 12,8%
actives Tripicolinate de chrome 200 PPB en premix 10%
Acide folique 4000 mg/kg en premix 1%
Composantes Argile accessoires Aluminosilicate Variation pour Ia maniabilite : Ingredients inertes : 10%
Aromate Remplissage Remplissage avec du mais moulu. 76% 90%
TOTAL 100% 100%
100%
Notes I. Formulation avant substitution : 14% d'activite poids/poids de polyphenols de deux sources, reglisse (12,5%) et cannelle (1,5%).
2. Formulation A: 14% d'activite poids/poids de polyphenols de 4 sources de polyphenols, rdglisse (4,5%), huile de th6(4,0%), menthe (2,5%) et cannelle (3,0%).
3. Les coumarines sont des acides phenoliques anticoagulantes.
4. Le tanin est un polyphdnol astringent 2.3.0) PROTOCOLE EXPERIMENTAL : La preparation du melange ses effectues en plusieurs etapes. L'etape 1 est la preparation d'un petit echantillon qui servait a evaluer les caracteristiques de base des ingredients. (Couleur, odeur, fluidite, densite, palatabilite).
L'etape 2 etait de verifier comment les ingredients pouvaient se manipuler en production laboratoire.
L'etape 3 etait la production d'echantillon test pour obtenir un seuil d'acceptabilite d'appetence pour les animaux.
Cet etape pouvait necessite plusieurs voyages aller retour entre la ferme et la cuisine laboratoire.
Lorsque le seuil d'acceptabilite etait atteint, un plus gros echantillon etait produit pour faire les tests d'experimentation sur les animaux. Les formules sont au tableau 2.
PROJET CHEZ LE PORC et LES STRESS NORMAUX:
LE PROJET: Le projet a trois phases, une phase 1 qui consiste a substituer des molecules actives anti-inflammatoires de la reglisse de chine (isoflavones, liquiritine, isoliquirie et formoneitine, ortho acetyle salicylate de sodium) par d'autres sources en provenance de 1'huile de the des bois, menthe poivre et cannelle (methyle salicylate, tannin, menthol, acide phenolique, aldehyde de cannelle). Et une deuxieme phase qui consiste a experimenter le melange sur des
Ingredients Formule avant Formule A: Groupe A Formule Placebo substitution % % %
Composantes Methyle salicylate de I'huile de 0,0% 4,0% AUCUN
phytoactives the O-salicylate de la reglisse 12,5% 4,5%
Acide phenolique 0,5% 2,5%
Aldehyde cinnamique 0,5% 1,0%
Coumarines 0,25% 1,0%
Tanin 0,25% 1,0%
Composantes Vitamine E 64 K U.I. ou en premix 12,8%
actives Tripicolinate de chrome 200 PPB en premix 10%
Acide folique 4000 mg/kg en premix 1%
Composantes Argile accessoires Aluminosilicate Variation pour Ia maniabilite : Ingredients inertes : 10%
Aromate Remplissage Remplissage avec du mais moulu. 76% 90%
TOTAL 100% 100%
100%
Notes I. Formulation avant substitution : 14% d'activite poids/poids de polyphenols de deux sources, reglisse (12,5%) et cannelle (1,5%).
2. Formulation A: 14% d'activite poids/poids de polyphenols de 4 sources de polyphenols, rdglisse (4,5%), huile de th6(4,0%), menthe (2,5%) et cannelle (3,0%).
3. Les coumarines sont des acides phenoliques anticoagulantes.
4. Le tanin est un polyphdnol astringent 2.3.0) PROTOCOLE EXPERIMENTAL : La preparation du melange ses effectues en plusieurs etapes. L'etape 1 est la preparation d'un petit echantillon qui servait a evaluer les caracteristiques de base des ingredients. (Couleur, odeur, fluidite, densite, palatabilite).
L'etape 2 etait de verifier comment les ingredients pouvaient se manipuler en production laboratoire.
L'etape 3 etait la production d'echantillon test pour obtenir un seuil d'acceptabilite d'appetence pour les animaux.
Cet etape pouvait necessite plusieurs voyages aller retour entre la ferme et la cuisine laboratoire.
Lorsque le seuil d'acceptabilite etait atteint, un plus gros echantillon etait produit pour faire les tests d'experimentation sur les animaux. Les formules sont au tableau 2.
PROJET CHEZ LE PORC et LES STRESS NORMAUX:
LE PROJET: Le projet a trois phases, une phase 1 qui consiste a substituer des molecules actives anti-inflammatoires de la reglisse de chine (isoflavones, liquiritine, isoliquirie et formoneitine, ortho acetyle salicylate de sodium) par d'autres sources en provenance de 1'huile de the des bois, menthe poivre et cannelle (methyle salicylate, tannin, menthol, acide phenolique, aldehyde de cannelle). Et une deuxieme phase qui consiste a experimenter le melange sur des
-13-pores en engraissement en conditions normale. La troisieme phase consiste a ajuste les ingredients accessoires inertes afin d'ameliorer sa maniabilite.
= La formulation est un additif alimentaire utilise a un ratio 1/1000 dans 1'aliment complet.
= La formulation a comme but d'essayer de demontrer l'effet inflammatoire peut-elle etre benefique chez des pores non challenges.
= L'efficacite de la formulation est evaluee par la presence de proteine inflammatoire dans le sang, et des resultats de performances zootechniques sur la mortalite et 1'efficacite alimentaire.
HYPOTHESE:
= Un additif alimentaire contenant suffisamment d'acides polyphenoliques anti-inflammatoire ainsi que du tripicolinate de chrome, aide a controler la reaction inflammatoire peut-il avoir un effet positif sur les parametres zootechniques.
= Il est possible de substituer des sources et molecules differentes en autant que les substituant ont les memes proprietes biologiques.
= Un animal expose a des ingredients differents, mais a de meme fonction devrait repondre de la meme maniere.
= Si les molecules anti-inflammatoires de la reglisse sont efficaces et que nous les substituons par d'autres rnolecules de meme nature, nous devrions avoir la meme reponse biologique.
Les ingredients a substitue sont : La reglisse Les ingredients substituant sont : Huiles de the des bois, menthe poivre et cannelle.
La principale raison de substitution est: La reglisse a forte concentration cree un melange qui fait des precipites.
MATERIELS ET METHODES
Dosages de 1'additif en fonction du sexe Animals EVP-COMBI
Truies 2 kg / tm Verrats 1 k / tm Porcelets 2 kg / tm
= La formulation est un additif alimentaire utilise a un ratio 1/1000 dans 1'aliment complet.
= La formulation a comme but d'essayer de demontrer l'effet inflammatoire peut-elle etre benefique chez des pores non challenges.
= L'efficacite de la formulation est evaluee par la presence de proteine inflammatoire dans le sang, et des resultats de performances zootechniques sur la mortalite et 1'efficacite alimentaire.
HYPOTHESE:
= Un additif alimentaire contenant suffisamment d'acides polyphenoliques anti-inflammatoire ainsi que du tripicolinate de chrome, aide a controler la reaction inflammatoire peut-il avoir un effet positif sur les parametres zootechniques.
= Il est possible de substituer des sources et molecules differentes en autant que les substituant ont les memes proprietes biologiques.
= Un animal expose a des ingredients differents, mais a de meme fonction devrait repondre de la meme maniere.
= Si les molecules anti-inflammatoires de la reglisse sont efficaces et que nous les substituons par d'autres rnolecules de meme nature, nous devrions avoir la meme reponse biologique.
Les ingredients a substitue sont : La reglisse Les ingredients substituant sont : Huiles de the des bois, menthe poivre et cannelle.
La principale raison de substitution est: La reglisse a forte concentration cree un melange qui fait des precipites.
MATERIELS ET METHODES
Dosages de 1'additif en fonction du sexe Animals EVP-COMBI
Truies 2 kg / tm Verrats 1 k / tm Porcelets 2 kg / tm
-14-Parametres d'evaluation de la reponse experimentale Parametres de mesure Su lement pol henoli ue Biochimie a. Haptoglobine (oxidation cellulaire) Oui b. CPK: (degenerescence musculaire) Oui c. Lactate: duree du stress) Oui Zootechnique :
a. Gain quotidien : Non b. Consommation alimentaire : Oui c. Consommation d'eau : Oui d. Fertilite : Oui Intervalle sevrage-saillie Oui Taux de reussite des inseminations Oui Taux de gestations (et de retours en chaleur) Oui Viabilite des porcelets au sevrage Oui e. Mortalite Oui Comportement :
a. Niveau d'agitation Oui b. Niveau d'a ressivite Oui Presence de maladie a. Types PRRS (porc) b. Incidences Oui c. Duree Oui RESULTATS
Tableau 5 Nombres d'animaux en Pouponniere Ferme :
Total Testes Contr6le Tableau 6 Nombre d'animaux en Engraissement Ferme Total Testes Contr6le
a. Gain quotidien : Non b. Consommation alimentaire : Oui c. Consommation d'eau : Oui d. Fertilite : Oui Intervalle sevrage-saillie Oui Taux de reussite des inseminations Oui Taux de gestations (et de retours en chaleur) Oui Viabilite des porcelets au sevrage Oui e. Mortalite Oui Comportement :
a. Niveau d'agitation Oui b. Niveau d'a ressivite Oui Presence de maladie a. Types PRRS (porc) b. Incidences Oui c. Duree Oui RESULTATS
Tableau 5 Nombres d'animaux en Pouponniere Ferme :
Total Testes Contr6le Tableau 6 Nombre d'animaux en Engraissement Ferme Total Testes Contr6le
-15-RESULTATS ZOOTECHNIOUES
Tableau 7 Gain en pouponniere sur de porcelet EVPP Contrale-Placebo Poids d'entree 5,55 kg 5,56 kg Poids de sortie 29,25 kg 24,21 kg Nbrs de 'ours 54 54 Gain / 'our 438 345 % de mortalft 4,98% 9,62%
Tableau 8 Gain en engraissement EVPP Controle-Placebo Poids d'entr6e 21,67 kg 21,88 kg Poids de sortie 108,90 kg 107,12 kg Nbrs de 'ours 92 94 Index 110,04 109,80 % de mortalite 4,59% 11,90%
Gain/jour 948 907 3.0) CONCLUSION ET COMMENTAIRES : Nos resultats confirment nos hypotheses sur l'importance du contr6le de I'inflammation chez le porc avec nos melanges antioxydants, polyphenols et vitamines.
Comme il apparalt que le porc est en inflammation chronique, celle-ci serait 1'element declencheur de plusieurs problemes de resistance aux maladies. Puisque nos resultats d6montrent un taux de proteine inflammatoire plus bas. Nos nouveaux melanges (formulations) di~montrent un effet aussi nouveau innatendu.
Tableau 7 Gain en pouponniere sur de porcelet EVPP Contrale-Placebo Poids d'entree 5,55 kg 5,56 kg Poids de sortie 29,25 kg 24,21 kg Nbrs de 'ours 54 54 Gain / 'our 438 345 % de mortalft 4,98% 9,62%
Tableau 8 Gain en engraissement EVPP Controle-Placebo Poids d'entr6e 21,67 kg 21,88 kg Poids de sortie 108,90 kg 107,12 kg Nbrs de 'ours 92 94 Index 110,04 109,80 % de mortalite 4,59% 11,90%
Gain/jour 948 907 3.0) CONCLUSION ET COMMENTAIRES : Nos resultats confirment nos hypotheses sur l'importance du contr6le de I'inflammation chez le porc avec nos melanges antioxydants, polyphenols et vitamines.
Comme il apparalt que le porc est en inflammation chronique, celle-ci serait 1'element declencheur de plusieurs problemes de resistance aux maladies. Puisque nos resultats d6montrent un taux de proteine inflammatoire plus bas. Nos nouveaux melanges (formulations) di~montrent un effet aussi nouveau innatendu.
-16-EXEMPLE II
EFFET DES POLYPHENOLS ISSU DES HUILES DE THE DES BOIS, MENTHE
POIVRE ET DE CANNELLE COMME ADDITIF DE CONTRO^LE DES STRESS CHEZ
LE VEAU DE GRAIN
Abstract : Le stress est un probleme de production extremement grave. Le stress semble le principal element responsable de la majorite des pertes de production. Le stress est une reaction naturelle de l'organisme. Le stress est un mecanisme inflammatoire qui inhibe la production toutes les autres fonctions du corps pour permettre dans un premier temps de produire du sucre et ainsi etre en mesure de repondre aux attaques externes. (The mechanisms of body function 1984).
Les quatre dernieres annees ont favorise des nouvelles approches de production animale et 1'ajout de nouvelles alternatives qui permettent de reduire les problemes du stress.
(Bristol University UK, animal welfare guide 2005). L'alimentation est aussi un moyen de reduire les stress ou du moins a aide de les controler. L,'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser un meilleur equilibre metabolique. L'objectif de cet ouvrage etait de demontrer si il est possible par I'alimentation d'augmenter la tolerance ou resistance aux differents stress d'elevage chez le veau.
MATERIELS ET METHODES
INTRANTS : Comme a l'exemple 1 FORMULATIONS : Comme a 1'exemple 1 EVP(B) = supplement anti-inflarnmatoire vegetal bOVIN (porc) PROTOCOLE EXPERIMENTAL
Comme a 1'exemple 1.
Tableau 1 Concentrations EVP-COMBI
Veaux lait 2 / jour Veaux Grairi 1 / our
EFFET DES POLYPHENOLS ISSU DES HUILES DE THE DES BOIS, MENTHE
POIVRE ET DE CANNELLE COMME ADDITIF DE CONTRO^LE DES STRESS CHEZ
LE VEAU DE GRAIN
Abstract : Le stress est un probleme de production extremement grave. Le stress semble le principal element responsable de la majorite des pertes de production. Le stress est une reaction naturelle de l'organisme. Le stress est un mecanisme inflammatoire qui inhibe la production toutes les autres fonctions du corps pour permettre dans un premier temps de produire du sucre et ainsi etre en mesure de repondre aux attaques externes. (The mechanisms of body function 1984).
Les quatre dernieres annees ont favorise des nouvelles approches de production animale et 1'ajout de nouvelles alternatives qui permettent de reduire les problemes du stress.
(Bristol University UK, animal welfare guide 2005). L'alimentation est aussi un moyen de reduire les stress ou du moins a aide de les controler. L,'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser un meilleur equilibre metabolique. L'objectif de cet ouvrage etait de demontrer si il est possible par I'alimentation d'augmenter la tolerance ou resistance aux differents stress d'elevage chez le veau.
MATERIELS ET METHODES
INTRANTS : Comme a l'exemple 1 FORMULATIONS : Comme a 1'exemple 1 EVP(B) = supplement anti-inflarnmatoire vegetal bOVIN (porc) PROTOCOLE EXPERIMENTAL
Comme a 1'exemple 1.
Tableau 1 Concentrations EVP-COMBI
Veaux lait 2 / jour Veaux Grairi 1 / our
-17-PARAMETRES : Comme 6 I'exemple 1 sauf biochimie du sang 3.0) RESULTATS
3.1) ECHANTILLONNAGE
Tableau 2 Echantillonnage d'animaux utilise en fonction de la pouponniere Ferme Total Testes Contr8le Les fermes sur lequel nous avons fait 1'experimentation avaient une rotation de 2 pour les deux groupes testes. Chaque test a ete repete 12 fois dans 1'annee.
RESULTATS ZOOTECHNIQUES
Tableau 3 Gain en engraissement : 2 grammes par veaux par jour EVPB Controle-Placebo Poids d'entree 130,66 kg 131,18 kg Poids de sortie 349,7 kg 344,9 kg Nbrs de 'ours 145 145 Conversion 3,20 3,62 % de mortaiite 5,52% 10,55%
Gain quotidien 1.51 kg 1,47 kg Tableau 4 Gain en engraissement : 2 grammes par veaux par jour EVPB Controle-Placebo Poids d'entree 130,66 kg 131,18 kg Poids de sortie 349,7 kg 344,9 kg Nbrs de jours 145 145 Conversion 3,20 3,62 % de mortalite 5,52% 10,55%
Gain quotidien 1.51 kg 1,47 kg
3.1) ECHANTILLONNAGE
Tableau 2 Echantillonnage d'animaux utilise en fonction de la pouponniere Ferme Total Testes Contr8le Les fermes sur lequel nous avons fait 1'experimentation avaient une rotation de 2 pour les deux groupes testes. Chaque test a ete repete 12 fois dans 1'annee.
RESULTATS ZOOTECHNIQUES
Tableau 3 Gain en engraissement : 2 grammes par veaux par jour EVPB Controle-Placebo Poids d'entree 130,66 kg 131,18 kg Poids de sortie 349,7 kg 344,9 kg Nbrs de 'ours 145 145 Conversion 3,20 3,62 % de mortaiite 5,52% 10,55%
Gain quotidien 1.51 kg 1,47 kg Tableau 4 Gain en engraissement : 2 grammes par veaux par jour EVPB Controle-Placebo Poids d'entree 130,66 kg 131,18 kg Poids de sortie 349,7 kg 344,9 kg Nbrs de jours 145 145 Conversion 3,20 3,62 % de mortalite 5,52% 10,55%
Gain quotidien 1.51 kg 1,47 kg
-18-CONCLUSION ET COMMENTAIRES : Les resultats zootechniques demontrent que les veaux repondent de maniere similaire aux pores aux differents formulations polyphenols anti-inflammatoires. La conversion alimentaire semble beaucoup ameliorer. Nous pensons que cette amelioration est liee au principe de controle du stress en limitant la surproduction d'hormone lie au stress. Ainsi un animal ayant requ le melange polyphenols aurait un systeme digestif en mode optimum sur la digestion. Cependant nous devons faire des etudes afin de demontrer cet aspect.
Nous avons dtudie le lactate et le CPK pour demontrer que les taux de ses parametres sanguins sont plus faibles chez les animaux ayant re~u le melange polyphenols.
EXEMPLE III
Effet des polyphenols issu des huiles de the des bois, menthe poivre et cannelle de chine comme additif de controle des stress de la vache en relation avec le compte des cellules somatiques et la qualite de lait.
Abstract : La production laitiere moderne fait face a des problemes emergents tels que l'inflammation chronique des glandes mammaires. L'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser une meilleure sante des glandes. Le phenomene qu'engendre l'inflammation des glandes mammaire est une sur production des globules blancs. L'aliment.ation de polyphdnols aux proprietes anti-inflammatoire nous semble une voie a la reduction de compte somatique.
L'objectif de cet ouvrage etait de demontrer si il est possible par l'utilisation de polyphenols anti-inflammatoire de controler l'inflammation et de reduire le compte somatique.
LE PROJET: Le projet a deux phases, une phase 1 qui consiste a a substituer des molecules actives anti-inflammatoires de la reglisse de chine (isoflavones, liquiritine, isoliquirie et formoneitine, ortho acdtyle salicylate de sodium) par d'autres sources en provenance de I'huile de the des bois, menthe poivre et cannelle (methyle salicylate, tannin, menthol, acide phenolique, aldehyde de cannelle). Et une deuxieme phase qui consiste a experimenter le melange sur des vaches en conditions commerciale typique.
HYPOTHESE
La formulation anti-inflammatoire peut-elle fonctionne sur les probleme chronique de l'inflammation de la glande mammaire.
MATERIELS ET METHODES
INTRANTS : Comme a 1'exemple 1.
FORMULATIONS: Comme a 1'exemple 1.
Nous avons dtudie le lactate et le CPK pour demontrer que les taux de ses parametres sanguins sont plus faibles chez les animaux ayant re~u le melange polyphenols.
EXEMPLE III
Effet des polyphenols issu des huiles de the des bois, menthe poivre et cannelle de chine comme additif de controle des stress de la vache en relation avec le compte des cellules somatiques et la qualite de lait.
Abstract : La production laitiere moderne fait face a des problemes emergents tels que l'inflammation chronique des glandes mammaires. L'acquisition de connaissance sur les plantes aux proprietes anti-inflammatoires nous semble une voie interessante pour favoriser une meilleure sante des glandes. Le phenomene qu'engendre l'inflammation des glandes mammaire est une sur production des globules blancs. L'aliment.ation de polyphdnols aux proprietes anti-inflammatoire nous semble une voie a la reduction de compte somatique.
L'objectif de cet ouvrage etait de demontrer si il est possible par l'utilisation de polyphenols anti-inflammatoire de controler l'inflammation et de reduire le compte somatique.
LE PROJET: Le projet a deux phases, une phase 1 qui consiste a a substituer des molecules actives anti-inflammatoires de la reglisse de chine (isoflavones, liquiritine, isoliquirie et formoneitine, ortho acdtyle salicylate de sodium) par d'autres sources en provenance de I'huile de the des bois, menthe poivre et cannelle (methyle salicylate, tannin, menthol, acide phenolique, aldehyde de cannelle). Et une deuxieme phase qui consiste a experimenter le melange sur des vaches en conditions commerciale typique.
HYPOTHESE
La formulation anti-inflammatoire peut-elle fonctionne sur les probleme chronique de l'inflammation de la glande mammaire.
MATERIELS ET METHODES
INTRANTS : Comme a 1'exemple 1.
FORMULATIONS: Comme a 1'exemple 1.
-19-PROTOCOLE
LES DOSAGES:
Tableau 1 Dosages EVPB
~ VACHE 5 a 60 grammes jour.
Tableau 2 EVPB PROGRAMME DU DOSAGE
Semaine 1 2 3 4 5 6 Quantite journaliere en 60g 40g 30g 20g 20g 5g grammes PARAMETRES:
Parametres de mesure Su lement ol hLsnoli ue : EVPB
COMPTE SOMATIQUE I
PRODUCTION DE LAIT
PROTEINE DU LAIT
GRAS DU LAIT
LES DOSAGES:
Tableau 1 Dosages EVPB
~ VACHE 5 a 60 grammes jour.
Tableau 2 EVPB PROGRAMME DU DOSAGE
Semaine 1 2 3 4 5 6 Quantite journaliere en 60g 40g 30g 20g 20g 5g grammes PARAMETRES:
Parametres de mesure Su lement ol hLsnoli ue : EVPB
COMPTE SOMATIQUE I
PRODUCTION DE LAIT
PROTEINE DU LAIT
GRAS DU LAIT
-20-RESULTATS
Tableau 4 Evolution de la productivite des vaches recevant 5 grammes par jour de melange anti-inflammatoire.
Pourcentage de vache par groupe de production Production faible 28,32% 24,98% 30,67% 30,11% 25,65%
(501b et moins) Production 69,26% 70,84% 66,84 % 66,84% 73,24%
moyenne a forte (51 a 101 + Ib) Nombre de 537 549 538 558 538 vache
Tableau 4 Evolution de la productivite des vaches recevant 5 grammes par jour de melange anti-inflammatoire.
Pourcentage de vache par groupe de production Production faible 28,32% 24,98% 30,67% 30,11% 25,65%
(501b et moins) Production 69,26% 70,84% 66,84 % 66,84% 73,24%
moyenne a forte (51 a 101 + Ib) Nombre de 537 549 538 558 538 vache
-21-Tableau 5 Amelioration de la pualite du lait (SCC) produits par des vaches recevant 5 grammes par iour de melange anti-inflammatoire Pourcentage de vache par groupe de compta somatique cellulaire Compte SCC moins de 200,000 70,10% 69,02% 68,21% 68,63% 75,48%
(Producteur reVoit une prime de qualite.) Compte SCC plus de 200,000 27,57% 26,90% 28,82 % 28,32% 23,41%
Nombre de vache 537 549 538 558 538 CONCLUSION
Les resultats demontrent les effets benefiques de nos nouvelles formulations sur les comptes cellulaires (SCC) dans le lait chez la vache. L'administration orale de nos formulations demontre une reduction significative des SCC dans les echantillons de lait dans le pis, ce qui reflete donc une amelioration du statut immunitaire de 1'animal et de la reduction de 1'inflammation de la glande mammaire et des infections de celle-ci.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
(Producteur reVoit une prime de qualite.) Compte SCC plus de 200,000 27,57% 26,90% 28,82 % 28,32% 23,41%
Nombre de vache 537 549 538 558 538 CONCLUSION
Les resultats demontrent les effets benefiques de nos nouvelles formulations sur les comptes cellulaires (SCC) dans le lait chez la vache. L'administration orale de nos formulations demontre une reduction significative des SCC dans les echantillons de lait dans le pis, ce qui reflete donc une amelioration du statut immunitaire de 1'animal et de la reduction de 1'inflammation de la glande mammaire et des infections de celle-ci.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
-22-
Claims (28)
1. A food supplement composition comprising at least one polyphenol compound, at least one antioxidant compound, and at least one vitamin.
2. The food supplement composition of claim 1, wherein said polyphenol compound is obtained from a plant extract.
3. The food supplement composition of claim 1, wherein said polyphenol compound is a polyphenolic acid.
4. The food supplement composition of claim 1, wherein said plant extract antioxidant is
5. The food supplement composition of claim 1, wherein said vitamin is an antioxidant vitamin.
6. The food supplement composition of claim 1, wherein said vitamin is vitamin D.
7. The food supplement composition of claim 1, wherein said said polyphenol is in proportion of 0.1% (w/v or w/w) to 25% (w/v or w/w), said anti-oxidant compound in proportion of 0.1% (w/v or w/w) to 20% (w/v or w/w), and said vitamin in proportion of 0.1%(w/v or w/w) to 30% (w/v or w/w).
8. A food supplement composition as claimed in any one of claims 1 to 7 which provides a concentration of methyl salicylate or an analog thereof at a level from 0.01 mg to 100 mg per kilogram body weight per day or above.
9. A food supplement composition as claimed in any one of claims 1 to 8, comprising a probiotic microorganism.
10. The food supplement composition of claim 9, wherein said probiotic microorganism is a yeast, a bacteria, or a combination thereof.
11. The food supplement composition of claim 8 or 9, wherein said probiotic microorganism is living or dead.
12. A food supplement as claimed in anyone of claims 1 to 11, wherein a portion of the anti-oxidant is provided by a natural source and a portion of the anti-oxidant is provided by a synthetic source.
13. A food supplement for reducing systemic inflammation, localised inflammation, body temperature, or cellular oxidation, comprising a food supplement composition as described in anyone of claims 1 to 12.
14. A method for reducing body temperature, systemic inflammation, localised inflammation, or cellular oxidation, said method comprising the step of administering orally to said animal or a human a composition as described in anyone of claims 1 to 13.
15. A method for improving fertility of an animal or a human comprising giving orally to said animal or human the food composition of anyone of claims 1 to 13.
16. A method for increasing the growth rate of an animal or a human comprising giving orally to said animal or a human the food composition of anyone of claims 1 to 13.
17. A method for calming an animal or a human comprising giving orally to said animal or human the food composition of anyone of claims 1 to 13.
18. A method for reducing body shrink of an animal or a human during a stress period comprising giving orally to said animal or human the food composition of anyone of claims 1 to 13 at least before, during, or after said stress period.
19. A method for increasing the number of eggs per bird comprising giving orally to said bird the food composition of anyone of claims 1 to 13.
20. A method for reducing diarrhea of an animal or a human comprising giving orally to said animal or human the food composition of anyone of claims 1 to 13.
21. A method for increasing wounding comprising giving orally to said animal or human the food composition of anyone of claims 1 to 13.
22. A food composition for improving fertility of an animal or a human comprising the food composition of anyone of claims 1 to 13.
23. A food composition for increasing the growth rate of an animal or a human comprising the food composition of anyone of claims 1 to 13.
24. A food composition for calming an animal or a human comprising the food composition of anyone of claims 1 to 13.
25. A food composition for reducing body shrink of an animal or a human during a stress period comprising the food composition of anyone of claims 1 to 13.
26. A food composition for increasing the number of eggs per bird comprising the food composition of anyone of claims 1 to 13.
27. A food composition for reducing diarrhea of an animal or a human comprising the food composition of anyone of claims 1 to 13.
28. A food composition for increasing wounding comprising the food composition of anyone of claims 1 to 13.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002618380A CA2618380A1 (en) | 2008-01-23 | 2008-01-23 | Feed additive and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002618380A CA2618380A1 (en) | 2008-01-23 | 2008-01-23 | Feed additive and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2618380A1 true CA2618380A1 (en) | 2009-07-23 |
Family
ID=40900683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002618380A Abandoned CA2618380A1 (en) | 2008-01-23 | 2008-01-23 | Feed additive and uses thereof |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2618380A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011052687A1 (en) * | 2011-08-12 | 2013-02-14 | Lohmann Animal Health Gmbh | Use of antioxidants |
CN114304393A (en) * | 2021-12-20 | 2022-04-12 | 广州合诚三先生物科技有限公司 | Plant composition and preparation method and application thereof |
WO2023137548A1 (en) * | 2022-01-20 | 2023-07-27 | Nat-Phen Nutrition | Anti-inflammatory feed formulation and uses thereof |
-
2008
- 2008-01-23 CA CA002618380A patent/CA2618380A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011052687A1 (en) * | 2011-08-12 | 2013-02-14 | Lohmann Animal Health Gmbh | Use of antioxidants |
WO2013024067A1 (en) | 2011-08-12 | 2013-02-21 | Lohmann Animal Health Gmbh | Use of antioxidants for improving animal health |
CN114304393A (en) * | 2021-12-20 | 2022-04-12 | 广州合诚三先生物科技有限公司 | Plant composition and preparation method and application thereof |
WO2023137548A1 (en) * | 2022-01-20 | 2023-07-27 | Nat-Phen Nutrition | Anti-inflammatory feed formulation and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Effects of Oridonin on growth performance and oxidative stress in broilers challenged with lipopolysaccharide | |
Giannenas et al. | Effect of supplementing feed with oregano and/or alpha-tocopheryl acetate on growth of broiler chickens and oxidative stability of meat | |
Berry et al. | The Middle Eastern and biblical origins of the Mediterranean diet | |
Hajati et al. | The effect of grape seed extract and vitamin C feed supplements carcass characteristics, gut morphology and ileal microflora in broiler chickens exposed to chronic heat stress | |
Florou-Paneri et al. | Performance of chickens and oxidative stability of the produced meat as affected by feed supplementation with oregano, vitamin C, vitamin E and their combinations | |
Brenes et al. | Effect of grape pomace concentrate and vitamin E on digestibility of polyphenols and antioxidant activity in chickens | |
Florou-Paneri et al. | Oregano herb versus oregano essential oil as feed supplements to increase the oxidative stability of turkey meat | |
Zeweil et al. | Pomegranate peel as a natural antioxidant boosts bucks' fertility under Egyptian summer conditions | |
US20080254135A1 (en) | Resveratrol-containing compositions for general health and vitality | |
JP2010503609A (en) | Kiwi extract | |
US20100004344A1 (en) | Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition | |
Desoky et al. | Effects of ginger and bee propolis on the performance, carcass characteristics and blood constituents of growing Japanese quail | |
Zhong et al. | Dietary tea catechin inclusion changes plasma biochemical parameters, hormone concentrations and glutathione redox status in goats | |
El-Ratel et al. | Productive performance, carcass traits, lipid profile, antioxidants and immunity of growing rabbits treated with gum Arabic under Egyptian summer condition | |
Rohdewald | Update on the clinical pharmacology of Pycnogenol (R) | |
Ge et al. | Cardioprotective properties of quercetin in fescue toxicosis-induced cardiotoxicity via heart-gut axis in lambs (Ovis Aries) | |
Zhang et al. | Antioxidant Activity of Powder and the Effect on Hepatic and Intestinal Antioxidant Indices in Broiler Chickens | |
CA2618380A1 (en) | Feed additive and uses thereof | |
JP2006298887A (en) | Active oxygen-removing agent, skin elasticity-retaining agent, anti-oxidizing action auxiliary | |
Chen et al. | High-genistin isoflavone supplementation modulated erythrocyte antioxidant enzymes and increased running endurance in rats undergoing one session of exhausting exercise–a pilot study | |
Ruben et al. | Effects of dietary thyme and oregano essential oils entrapped in chitosan and Canarium charcoal stable matrix on growth performances in broiler chickens | |
NO330566B1 (en) | Use of a fat-soluble vitamin absorption-increasing effective amount of L-carnitine in the preparation of a diet or drug containing a fat-soluble vitamin. | |
CA2585010A1 (en) | Resveratrol-containing compositions for general health and vitality | |
US8617544B2 (en) | Compositions and methods for controlling lipid metabolism | |
KR102582313B1 (en) | Composition for improving joint health by reducing body fat in companion dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |